Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (16048)	2/28/1998 11:00:00 AM
From: Machaon	Respond to of 32384

Lehman has an interesting analysis about the war on cancer. LGND is mentioned as one of the biotech stocks that they favor in the oncology area. Nothing really new, since they already rate LGND a 1-buy, but interesting reading. lehman.com The analysis is contained in the item titled: "Biotechnology: Profiting" Good luck, Bob

To: Henry Niman who wrote (16048)	2/28/1998 8:41:00 PM
From: WTDEC	Read Replies (1) \| Respond to of 32384

Henry, Bernie, Herbert, P2, Tony, et. al.-- There is a very comprehensive article in the Feb. 21-27 issue of The Economist entitled "The Pharmaceutical Industry: Better,Faster,Cheaper". If you have not seen it, I strongly recommend it as it includes coverage of many biotechs, along with what they see as major trends. I think there are many aspects of the article which investors in the sector should consider. I apologize if this article was already mentioned. If you have a problem finding a copy of the Feb. 21 issue (the Feb. 28 issue is now out), I'd be happy to fax a copy to active contributors to this thread who e-mail a fax number to me. Regards, wtd